BSP Pharmaceuticals S.p.A. (manufacturing of unpackaged product, primary packaging, quality control of finished product batches)

The drug is intended for the treatment of adults with CD30-positive Hodgkin lymphoma (in various stages and forms), systemic anaplastic large cell lymphoma, as well as certain subtypes of T-cell lymphoma of the skin.

Dosage form: powder for concentrate for infusion solution

ATC: L01FX05